World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
123
Citations
76024
World Ranking
3286
National Ranking
1809

Jeffrey S. Ross publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jeffrey S. Ross sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,261 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jeffrey S. Ross D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jeffrey S. Ross sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 123 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jeffrey S. Ross is affiliated with Foundation Medicine in the United States. Their research is primarily focused on cancer genomics, diagnostics, and treatment. The body of work covers several key areas within medicine and molecular biology, with a strong emphasis on oncology and related subfields.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, subfields prominently represented in their publications are:

  • Surgery
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Molecular Biology

The primary topics of research include:

  • Cancer Genomics and Diagnostics
  • Bladder and Urothelial Cancer Treatments
  • Cancer Immunotherapy and Biomarkers
  • Urinary and Genital Oncology Studies
  • Prostate Cancer Treatment and Research
  • Genetic factors in colorectal cancer
  • Lung Cancer Treatments and Mutations

Jeffrey S. Ross has contributed to a number of research papers, some of which are:

  • Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms (2021, Clinical Cancer Research)
  • Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer (2020, European Urology)
  • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity (2020, JCO Precision Oncology)
  • Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma (2022, Nature Communications)
  • Clinicopathologic Characteristics of BRG1-Deficient NSCLC (2020, Journal of Thoracic Oncology)

Their frequent co-authors include:

  • Richard S.P. Huang
  • Andrea Necchi
  • Natalie Danziger
  • Dean C. Pavlick
  • Douglas I. Lin

Jeffrey S. Ross has published extensively in several prominent scientific venues. The most common journals for their work are:

  • Journal of Clinical Oncology
  • The Oncologist
  • Annals of Oncology
  • Cancer Research
  • JCO Precision Oncology

Best Publications

  • Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

    Zachary R. Chalmers;Caitlin F. Connelly;David Fabrizio

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

    Garrett M Frampton;Alex Fichtenholtz;Geoff A Otto;Kai Wang

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

    Jeffrey S. Ross;Jonathan A. Fletcher

  • The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

    Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai

  • Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

    Doron Lipson;Marzia Capelletti;Roman Yelensky;Geoff Otto

  • HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

    Michael F. Press;Leslie Bernstein;Patricia A. Thomas;Lorraine F. Meisner

  • The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

    Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Gerald P. Linette;Gerald P. Linette;James Stec

  • Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

    Garrett M. Frampton;Siraj M. Ali;Mark Rosenzweig;Juliann Chmielecki

  • Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer

    Rinath Jeselsohn;Roman Yelensky;Gilles Buchwalter;Gilles Buchwalter;Garrett Frampton

  • Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer

    Jeffrey S. Ross;Christine E. Sheehan;Hugh A. G. Fisher;Ronald P. Kaufman

  • Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

    Luca Gianni;Milvia Zambetti;Kim Clark;Joffre Baker

  • Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

    Jason K. Sicklick;Shumei Kato;Ryosuke Okamura;Maria Schwaederle

  • Lumbar degenerative disk disease.

    Michael T. Modic;Jeffrey S. Ross

  • Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.

    Thomas Wiesner;Jie He;Roman Yelensky;Rosaura Esteve-Puig

  • Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study

    Andrea Necchi;Andrea Anichini;Daniele Raggi;Alberto Briganti

  • Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

    Alexander Drilon;Lu Wang;Adnan Hasanovic;Yoshiyuki Suehara

  • Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

    Justin M. Balko;Jennifer M. Giltnane;Kai Wang;Luis J. Schwarz

  • Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

    Roman Rouzier;Radhika Rajan;Peter Wagner;Kenneth R. Hess

Frequent Co-Authors

Siraj M. Ali
Siraj M. Ali Foundation Medicine
Philip J. Stephens
Philip J. Stephens Foundation Medicine
Garrett M. Frampton
Garrett M. Frampton Foundation Medicine
Lajos Pusztai
Lajos Pusztai Yale University
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine
Shridar Ganesan
Shridar Ganesan Rutgers, The State University of New Jersey
W. Fraser Symmans
W. Fraser Symmans The University of Texas MD Anderson Cancer Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Gerald P. Linette
Gerald P. Linette University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond a traditional MD, there are many flexible, online options for those interested in healthcare careers or advancing their qualifications. Nursing offers several entry points, with programs like the fastest lpn program letting aspiring nurses quickly begin their careers as licensed practical nurses.

For licensed nurses looking to specialize, there are pmhnp online programs that allow RNs to become Psychiatric Mental Health Nurse Practitioners, meeting a growing need for mental health professionals.

If you’re interested in the leadership or administrative side of healthcare, consider pursuing a Master of Healthcare Administration. Many of the best online mha programs combine affordability, flexibility, and industry relevance—helping you balance education with work and other commitments.

Cost is a common concern, but it’s worth researching options such as the cheapest online master degree in healthcare administration to find accredited, budget-friendly pathways. These programs can help propel your career forward without incurring significant debt.

Best Scientists Citing Jeffrey S. Ross

Trending Scientists

Recently Published Articles